|Day Low/High||169.30 / 170.99|
|52 Wk Low/High||151.47 / 179.92|
Despite recent talc powder risks, the long-term earnings power of this 'Dividend King' has not deteriorated.
But even in bear markets you get spikes, usually short sharp ones.
We are absolutely due for a rip-your-face-off rally in the wake of entering a bear market.
Remember, though, playing defense is very different than leaving the stadium altogether.
These are currently situations where companies are facing serious lawsuits.
Are machines jumping on Johnson & Johnson's human risk headlines?
Putting J&J stock's selloff in a graphic illustrates the market's swift and violent reaction to the Reuters report.
Shares continue to fall on Monday after Friday's swift descent.
I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
Many analysts advise buying the shares on weakness because it's attractively priced.
JNJ ended the day and week in a vulnerable position and we are seeing further weakness today.
The market appears to still be spooked by JNJ as shares are set to open at their lowest level since July amid the Reuters articles fallout.
Now the unnerving thing about this market is that when it gets on a negative roll it blows through all convention.
While headline-chasing algorithms alter expected outcomes based on fundamental analysis, technical analysis remains valid.
Johnson & Johnson has survived some unfortunate news events in the past, but I would not take that as a good technical reason to hold the stock.
Unimpressed Equity markets headed lower as the regular Friday trading session extended into it's second and third hours. The way down has been led, not by Adobe , not by Costco , but by Johnson & Johnson . I have been known to make limited attempts ...
Use it to your advantage or don't use it at all.
It's done without much thought even though their companies are doing amazingly well.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
With all the major indices trading below 50-day moving averages, it would take a big move up to be meaningful.
Pfizer pushes higher on price increases.
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.